Biblio

Author Title [ Type

] Year

Filters: Author is Thiede, Christian [Clear All Filters]

Journal Article

Schneider M, Rolfs C, Trumpp M, Winter S, Fischer L, Richter M, Menger V, Nenoff K, Grieb N, Metzeler KH, et al. Activation of distinct inflammatory pathways in subgroups of LR-MDS. Leukemia. 2023.

Hernández-Malmierca P, Vonficht D, Schnell A, Uckelmann HJ, Bollhagen A, Mahmoud MAA, Landua S-L, van der Salm E, Trautmann CL, Raffel S, et al. Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. Cell Stem Cell. 2022;29(5):760-775.e10.

de Vries ISNaarmann, Sackmann Y, Klein F, Ostareck-Lederer A, Ostareck DH, Jost E, Ehninger G, Brümmendorf TH, Marx G, Röllig C, et al. Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region. Leuk Res. 2018;76:15-23.

Fleischmann M, Scholl S, Frietsch JJ, Hilgendorf I, Schrenk K, Hammersen J, Prims F, Thiede C, Hochhaus A, Schnetzke U. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia. J Cancer Res Clin Oncol. 2022.

Rapin N, Bagger FOtzen, Jendholm J, Mora-Jensen H, Krogh A, Kohlmann A, Thiede C, Borregaard N, Bullinger L, Winther O, et al. Comparing cancer vs. normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. Blood. 2013.

Crysandt M, Brings K, Beier F, Thiede C, Brümmendorf TH, Jost E. Germline predisposition to myeloid malignancies appearing in adulthood. Expert Rev Hematol. 2018.

Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C, Thiede C, Hänel M, Schäfer-Eckart K, Aulitzky W, et al. High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial. J Clin Oncol. 2013.

Panagiota V, Meggendorfer M, Kubasch ASophie, Gabdoulline R, Krönke J, Mies A, Shaswar R, Kandziora C, Klement P, Schiller J, et al. Impact of PPM1D Mutations in Patients with Myelodysplastic Syndrome and Deletion of Chromosome 5q. Am J Hematol. 2021.

Ravandi F, Cloos J, Buccisano F, Dillon R, Döhner K, Freeman SD, Hourigan CS, Ossenkoppele GJ, Roboz GJ, Subklewe M, et al. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel. Am J Hematol. 2023.

Jayavelu AKumar, Wolf S, Buettner F, Alexe G, Haupl B, Comoglio F, Schneider C, Doebele C, Fuhrmann DC, Wagner S, et al. The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell. 2022.

Frick M, Chan W, Arends CMaximilian, Hablesreiter R, Halik A, Heuser M, Michonneau D, Blau O, Hoyer K, Christen F, et al. Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2018:JCO2018792184.

Eckardt J-N, Röllig C, Metzeler K, Heisig P, Stasik S, Georgi J-A, Kroschinsky F, Stölzel F, Platzbecker U, Spiekermann K, et al. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles. Commun Med (Lond). 2023;3(1):68.